Literature DB >> 22434102

Association between HLA-DQB1 gene and patients with acute lymphoblastic leukemia (ALL).

Elias Orouji1, Jalil Tavakkol Afshari, Zahra Badiee, Abbas Shirdel, Afrouz Alipour.   

Abstract

Acute lymphoblastic leukemia (ALL) affects both children and adults. Survival in ALL has improved in recent decades due to recognition of its biological heterogeneity. Although children have higher remission and cure rates than adults, both populations have benefited from these improvements. Our aim in this study is to determine the association between HLA-DQB1 genes with childhood and adult ALL patients. To define this association, we compared HLA-DQB1 allele frequencies and allele carrier frequencies in a cohort of 135 adults and children with ALL with 150 controls, using polymerase chain reaction with sequence-specific primers. Allele carrier frequencies in childhood ALL show a deficiency in DQ2 (*0201) (P 0.049 and RR 0.75), but an increase in DQ5 (*0501-*0504) and DQ7 (*0301, *0304) compared to the control group (P 0.001 RR 1.89, P 0.003 RR 1.48, respectively). Allele carrier frequencies in adult ALL indicated an increase in DQ5 (*0501-*0504) (P0.045 RR 2.28). Allelic frequencies in childhood ALL revealed the same increase in DQ5 and DQ7, and a decrease in DQ2. In adult ALL it shows a decrease in DQ7. Therefore, our results in adult ALL were similar to childhood ALL addressing DQ5 allele carriers, which showed an increase in both age groups. We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434102     DOI: 10.1007/s12185-012-1051-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

Review 1.  Genetic control of immune response and disease susceptibility by the HLA-DQ gene.

Authors:  Y Nishimura; N Kamikawaji; K Fujisawa; H Yoshizumi; M Yasunami; A Kimura; T Sasazuki
Journal:  Res Immunol       Date:  1991 Jun-Aug

2.  Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease.

Authors:  Ali-Akbar Amirzargar; Farideh Khosravi; Saied S Dianat; Kamran Alimoghadam; Fereidoun Ghavamzadeh; Bita Ansaripour; Batool Moradi; Behrooz Nikbin
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

3.  HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma.

Authors:  C M Jackow; J B McHam; A Friss; J Alvear; J R Reveille; M Duvic
Journal:  J Invest Dermatol       Date:  1996-09       Impact factor: 8.551

4.  HLA class II allele and haplotype frequencies in iranian patients with acute myelogenous leukemia and control group.

Authors:  Abdolfattah Sarafnejad; Farideh Khosravi; Kamran Alimoghadam; Saied Dianat; Bita Ansaripour; Batoul Moradi; Shahin Dorkhosh; Aliakbar Amirzargar
Journal:  Iran J Allergy Asthma Immunol       Date:  2006-09       Impact factor: 1.464

Review 5.  HLA disease associations: models for the study of complex human genetic disorders.

Authors:  G Thomson
Journal:  Crit Rev Clin Lab Sci       Date:  1995       Impact factor: 6.250

Review 6.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201.

Authors:  G Malcolm Taylor; Simon Dearden; Paul Ravetto; Michelle Ayres; Pamela Watson; Adiba Hussain; Mel Greaves; Freda Alexander; Osborn B Eden
Journal:  Hum Mol Genet       Date:  2002-07-01       Impact factor: 6.150

8.  Preliminary evidence of an association between HLA-DPB1*0201 and childhood common acute lymphoblastic leukaemia supports an infectious aetiology.

Authors:  G M Taylor; M D Robinson; A Binchy; J M Birch; R F Stevens; P M Jones; T Carr; S Dearden; D A Gokhale
Journal:  Leukemia       Date:  1995-03       Impact factor: 11.528

9.  Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis.

Authors:  V R Bonagura; F P Siegal; A L Abramson; F Santiago-Schwarz; M E O'Reilly; K Shah; D Drake; B M Steinberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

10.  Evidence that an HLA-DQA1-DQB1 haplotype influences susceptibility to childhood common acute lymphoblastic leukaemia in boys provides further support for an infection-related aetiology.

Authors:  G M Taylor; S Dearden; N Payne; M Ayres; D A Gokhale; J M Birch; V Blair; R F Stevens; A M Will; O B Eden
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more
  4 in total

1.  The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.

Authors:  Charlie Zhong; Loren Gragert; Martin Maiers; Brian T Hill; Jean Garcia-Gomez; Ketevan Gendzekhadze; David Senitzer; Joo Song; Dennis Weisenburger; Leanne Goldstein; Sophia S Wang
Journal:  Leuk Lymphoma       Date:  2019-06-19

2.  LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL.

Authors:  Xuanmei Huang; Libin Huang; Qing Xie; Ling Zhang; Shaohui Huang; Mingye Hong; Jiangbin Li; Zunnan Huang; Hua Zhang
Journal:  Biomark Res       Date:  2021-06-10

Review 3.  Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence.

Authors:  Kevin Y Urayama; Pamela D Thompson; Malcolm Taylor; Elizabeth A Trachtenberg; Anand P Chokkalingam
Journal:  Front Oncol       Date:  2013-12-12       Impact factor: 6.244

Review 4.  Genetics of blood malignancies among Iranian population: an overview.

Authors:  Majid Ghayour-Mobarhan; Amir Sadra Zangouei; Seyed Mohammad Hosseinirad; Majid Mojarrad; Meysam Moghbeli
Journal:  Diagn Pathol       Date:  2020-05-06       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.